Antibodies

Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Discovering markers of disease progression in patients with MS treated with natalizumab 2:08
Discovering markers of disease progression in patients with MS treated with natalizumab
Charlotte Teunissen • 6 Oct 2021
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD 3:11
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD
Celia Oreja-Guevara • 14 Oct 2021
Delaying MS treatment to boost COVID-19 vaccination effects 4:37
Delaying MS treatment to boost COVID-19 vaccination effects
Anat Achiron • 12 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
The evolutionary importance of CGRP 2:21
The evolutionary importance of CGRP
Lawrence Robbins • 23 Sep 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world 1:56
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Piero Barbanti • 27 Sep 2021
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS 3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis • 20 Sep 2021
Parkinson’s disease: what’s to come in 2022? 3:20
Parkinson’s disease: what’s to come in 2022?
Angelo Antonini • 24 Sep 2021
BBB permeability changes predict treatment response to alemtuzumab in RRMS 5:26
BBB permeability changes predict treatment response to alemtuzumab in RRMS
Maria Højberg Knudsen • 1 Oct 2021
The future of biomarkers in MS: novel discoveries and defining protocols 2:12
The future of biomarkers in MS: novel discoveries and defining protocols
Charlotte Teunissen • 6 Oct 2021
Fingolimod and ocrelizumab prevent successful immune responses to COVID-19 vaccination in MS 5:26
Fingolimod and ocrelizumab prevent successful immune responses to COVID-19 vaccination in MS
Anat Achiron • 12 Oct 2021
The content of VJNeurology is intended for healthcare professionals